View all newsletters
Receive our newsletter – data, insights and analysis delivered to you


Preclinical Efficacy Services in Oncology and Skeletal Diseases

Pharmatest offers specialised research services for the pharmaceutical industry.

Itäinen Pitkäkatu 4 C, 5th floor,
Preclinical research services

Pharmatest offers specialised clinically predictive preclinical research services for the pharmaceutical industry.

Pharmatest provides full-service research solutions for oncology and skeletal diseases. The research models are designed to emphasise clinical relevance and predictivity.

Pharmatest can establish the proof-of-efficacy of drug candidates using cell culture assays and animal models.

The company has designed optimal study set-ups to test new drug candidates according to regulations of the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). It also offers specially designed studies for testing biosimilars and functional foods that require less extensive requirements.

Pharmatest can help establish the proof-of-efficacy of cancer drug candidates using its cell culture assays and animal models.
Intracardiac breast cancer bone metastasis models are available that act as predictive models of cancer-induced bone disease.
In osteoporosis animal models, Pharmatest offers specific study setups for testing new drug candidates according to the regulatory guidelines of FDA and EMEA, and for testing biosimilars and functional foods with less extensive regulatory requirements.
In oncology, Pharmatest is specialised in orthotopic and metastasis models that have increased clinical relevance and predictivity compared with traditionally used subcutaneous models that lack the proper microenvironment.
Pharmatest focus on high quality and clinical predictivity of data acquired. All research models have been fully optimised and validated with several years of extensive R&D work.

Cancer models

The company specialises in full-service efficacy testing of new cancer drug candidates. In vitro studies demonstrate what cancer cell lines are affected by test compounds and efficacy is confirmed in vivo in the company’s animal models using the same cell lines.

In vitro assays for cancer screening applications

Pharmatest’s in vitro cancer cell assays, including cell viability and cell invasion, are rapid and reliable screening tools for cancer drug discovery. They are available in automated high-throughput screening (HTS) platforms.

Cancer cell invasion is measured using the BD BioCoat FluoroBlok invasion system. Cell migration capacity through the Matrigel layer is determined, while cell invasion is quantified by post-labelling cancer cells with a fluorescent dye.

Clinically predictive cancer models

Pharmatest specialises in clinically predictive orthotopic and metastasis models of breast, prostate and pancreatic cancer, as well as multiple myeloma. They provide the proper tissue microenvironment, which is crucial since it is known to affect tumour growth, metastasis and drug resistance.

The clinical relevance and predictivity is relevantly increased over traditionally used subcutaneous models that lack the proper microenvironment.

Orthotopic and metastasis models

Orthotopic breast cancer models are available with human estrogen receptor positive MCF-7 cell line, triple negative human MDA-MB-231(SA) or mouse 4T1 cell lines. Tumour growth is monitored by measuring dimensions of the tumour at intervals.

Pharmatest’s intracardiac breast cancer bone metastasis models are predictive models of cancer-induced bone disease with radiography and dynamic fluorescence imaging to reveal illness progression.

The company provides orthotopic prostate cancer models with the androgen receptor positive, and PSA producing LNCaP cell line.

Models are also available with the androgen receptor negative PC-3 cell line that develops metastases to prostate-draining lymph nodes, in addition to intracardiac and intratibial models of prostate cancer bone metastasis, where radiography reveals the progression of bone metastases.

Pharmatest offers a mouse model of multiple myeloma that mirrors clinical conditions of myeloma bone disease in patients. The model responds to treatment and is ideal for testing efficacy of drug compounds against multiple myeloma, specifically active myeloma, which is characterised by osteolytic lesions. It involves inoculation of mouse multiple myeloma cells into the tail vein of immunocompetent mice.

Pharmatest also supplies an orthotopic pancreatic cancer model, which is suitable for testing efficacy of drug compounds against primary tumour growth and responds to treatment. The model involves a surgical procedure where human pancreatic adenocarcinoma cells are inoculated into the pancreas of immunodeficient mice.

Skeletal disease model

Pharmatest’s clinically predictive skeletal disease models include bone cell culture assays and animal models of osteoporosis and osteoarthritis, which can also be used for bone safety testing.

In vitro bone cell cultures

Pharmatest’s in vitro bone cell assays have been designed for pharmacodynamic testing of new therapeutic agents against osteoporosis and cancer-induced bone disease before entering animal studies. Separate assays are available for testing effects on differentiation and activity of bone forming osteoblasts and bone resorbing osteoclasts.

In vitro osteoblast assays involve culturing mesenchymal progenitor cells that are differentiated into mature osteoblasts. In vitro osteoclast assays involve culturing bone marrow derived osteoclast precursor cells that are differentiated into mature bone-resorbing osteoclasts.

Osteoporosis and osteoarthritis models

Pharmatest’s in vivo models of osteoporosis include:

  • Rat and mouse ovariectomy (OVX) models of postmenopausal osteoporosis
  • Rat orchidectomy (ORX) model of male osteoporosis
  • Mouse model of glucocorticoid-induced osteoporosis (GIO)

According to FDA and EMA regulations, all new therapies for postmenopausal osteoporosis should be tested in the rat OVX model.

The company’s in vivo models of osteoarthritis include:

  • Monoiodoacetate (MIA) model, where OA is caused chemically by intra-articular injection of MIA
  • Medial meniscal tear (MMT) and medial collateral ligament transection (MCLT), where OA is caused surgically by MMT and MCLT
  • Anterior cruciate ligament transection (ACLT), where OA is caused surgically by ACLT
  • ACLT and partial medial meniscectomy (pMMx), where OA is caused surgically by ACLT and pMMx
  • pMMX and ACLT models in rabbits

Bone analysis services

The following bone analysis methods are included in different disease models and are also offered as a standalone service:

  • Micro-computed tomography
  • Peripheral quantitative computed tomography
  • Radiographic imaging and image analysis
  • Full-service bone histomorphometry
  • Processing tissue samples for histological analysis
  • Bone ash weight and biomechanical testing
  • Biochemical markers of bone turnover in serum
  • Gene expression analysis using microarrays and bioinformatics services

Drug Efficacy Evaluation in Bone Metastasis Models

Metastatic and primary tumours are known to respond differently to chemotherapy. Therefore, when establishing drug efficacy it is important not to rely only on experiments in primary tumour models but to also study the test compound in metastasis models.

Pharmatest Credits Bruker for SkyScan 1276 in vivo micro-CT

After nine months’ experience, Pharmatest has given high credit to the performance of Bruker’s SkyScan 1276 High-Resolution and Fast In Vivo Desktop Micro-Computed Tomography (micro-CT), which was installed at its premises in February.

24 November 2017

Radiotherapy Expertise in Pharmatest

Having successfully worked with radioactive compounds for almost a decade, Pharmatest has strong expertise in testing efficacy of radiotherapies in preclinical oncology models, which was demonstrated in a recent scientific publication in collaboration with Bayer.

2 November 2017

Pharmatest Establishes Subsidiary in US

Pharmatest Services LLC is newly established US based contract research organization (CRO) operating in Massachusetts. It offers preclinical efficacy services in oncology and skeletal diseases. The company is a fully owned subsidiary of Pharmatest Services Ltd based in Finland.

8 June 2017

Pharmatest Services Announces the Purchase of New Bone Imaging Equipment

Pharmatest Services has purchased two new devices for bone imaging, the SkyScan 1276 high-resolution desktop in vivo Micro-computed tomography (mCT) system of Bruker and the Faxitron UltraFocus dual-energy X-ray absorptiometry (DXA) digital radiography system of DatecMedico.

11 October 2016


Itäinen Pitkäkatu 4 C, 5th floor

US Sales Offices (Boston)

300 Baker Ave. #300
Concord, MA 01742
United States of America

US Sales Offices (California)

501 W Broadway #800
San Diego, CA 92101
United States of America

China Agency Office

Guangzhou Gucon Biotech Co., Ltd
Rm.302-304, D#, Chuangxin Base
No.80, Lanyue Rd., Guangzhou Science City
Luogang, Guangzhou, Guangdong

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology